MARKET

AGEN

AGEN

Agenus
NASDAQ
3.470
+0.090
+2.66%
After Hours: 3.400 -0.07 -2.02% 19:57 05/14 EDT
OPEN
3.370
PREV CLOSE
3.380
HIGH
3.560
LOW
3.300
VOLUME
610.87K
TURNOVER
--
52 WEEK HIGH
19.69
52 WEEK LOW
1.380
MARKET CAP
95.14M
P/E (TTM)
-0.3276
1D
5D
1M
3M
1Y
5Y
1D
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10h ago
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
NASDAQ · 15h ago
HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral
Benzinga · 1d ago
Agenus Price Target Raised to $4.00/Share From $3.00 by Baird
Dow Jones · 1d ago
Agenus Is Maintained at Neutral by Baird
Dow Jones · 1d ago
Baird Maintains Neutral on Agenus, Raises Price Target to $4
Benzinga · 1d ago
Agenus price target raised to $4 from $3 at Baird
TipRanks · 1d ago
Agenus’s Regulatory and Clinical Developments Prompt Neutral Stance Amid Uncertain FDA Pathway
TipRanks · 1d ago
More
About AGEN
More
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Recently
Symbol
Price
%Change
    XQO
  • 21238.94
  • +1.54%

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.